Abstract:ABSTRACTBackgroundChronic hepatitis B (CHB) remains incurable due to the immune system’s tolerance towards the hepatitis B virus (HBV) surface antigen (HBsAg). This study aimed to achieve a functional cure by breaking HBV tolerance through immunotherapy.MethodsCHB patients were treated with either standard nucleotide analog (NA) therapy (Adefovir Dipivoxil, ADV) (cohort 1) or ADV combined with interferon-alpha (IFN-alpha) (cohort 2). Additionally, a third cohort received the THRIL-GM-Vac regimen: three low-dose GM-CSF injections followed by one dose of the HBV vaccine, alongside standard treatment.ResultsTHRIL-GM-Vac treatment (cohort 3) achieved a significant 2log10 reduction in HBsAg levels in 21.7% of participants compared to 0% and 4.17% in cohorts 1 and 2, respectively. Furthermore, THRIL-GM-Vac significantly reduced HBV-specific tolerogenic T cells (Tregs), explaining the sustained HBsAg decrease. Upregulation of anti-HBV T cell responses confirmed THRIL-GM-Vac’s ability to disrupt HBV tolerance and enhance HBsAg-specific cellular immunity. This suggests its potential effectiveness in treating individuals with moderate to low HBsAg levels.ConclusionTHRIL-GM-Vac treatment in cohort 3 resulted in 8.7% HBsAg clearance alongside Treg depletion and enhanced anti-viral T cell responses. These findings present a promising strategy to overcome immunotolerance and potentially combat chronic HBV infection.Significance of This StudyWhat Is Already Known- Persistent viral replication in chronic HBV infection increases the risk of disease progression. Achieving virological suppression is crucial, yet patients with HBsAg still face adverse outcomes, like hepatocellular carcinoma (HCC).- The ideal treatment goal is a functional cure, or HBsAg loss, which significantly improves clinical outcomes.- Current treatments include Nucleos(t)ide analogs (NAs) and Interferon (IFNs), with NAs being potent in viral replication inhibition but less effective in HBsAg clearance. IFNs offer a modestly better HBsAg loss rate.- Combining NAs with IFNs or switching to IFNs has shown some improvement in HBsAg seroclearance in clinical trials.New Findings- Previous studies highlighted GM-CSF as potential vaccine adjuvants that boost antitumor and antiviral immunity. Our study demonstrates that a combination of GM-CSF therapy and HBV vaccination (THRIL-GM-Vac), along with ADV and IFN-α as standard treatment, significantly reduces HBsAg levels and enhances anti-HBsAg cell-mediated immunity compared to the standard treatments.- Specifics include a considerable decrease of HBsAg in 43.5% of patients, with 21.7% exhibiting a major reduction, including HBsAg seroclearance in 8.7% of participants. This response coincided with an increase in cellular immunity markers.Clinical Implications- The THRIL-GM-Vac strategy, when combined with conventional antiviral treatments, opens avenues for achieving a functional HBV cure in a more significant proportion of patients.- Our findings suggest that targeting Treg-dependent immunotolerance correlates with HBsAg reduction, providing a potential immune-surrogate endpoint to predict treatment efficacy.- This approach offers a promising direction for future research and treatment strategies to meet unmet medical needs in chronic HBV treatment.

Longterm Outcome of Therapeutic Vaccination with a Third Generation Pre-S/S HBV Vaccine (PreHevbrioR) of Chronically HBV Infected Patients

HBcrAg, Pg RNA and HBsAg Dynamically Supervise the Seroconversion of HBsAg with Anti-Viral Therapy "loss of HBsAg" Maybe Not a Good End-Point of Anti-Viral Therapy

Results of a Phase III Clinical Trial with an HBsAg-HBIG Immunogenic Complex Therapeutic Vaccine for Chronic Hepatitis B Patients: Experiences and Findings.

Seroclearance of HBsAg in Chronic Hepatitis B Patients after a Tolerance Breaking Immuno-Therapy: GM-CSF, Followed by A Recombinant HBV Vaccine

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Serum Hbeag Sero-Conversion Correlated with Decrease of Hbsag and Hbv Dna in Chronic Hepatitis B Patients Treated with A Therapeutic Vaccine

Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers

Association Between Negative Results from Tests for HBV DNA and RNA and Durability of Response after Discontinuation of Nucles(t)ide Analogue Therapy.

Hepatitis B Virus Immunization with an Adjuvant Containing Vaccine after Liver Transplantation for Hepatitis B-related Disease: Failure of Humoral and Cellular Immune Response

Hepatitis B Virus Vaccination in HIV: Immunogenicity and Persistence of Seroprotection up to 7 Years Following a Primary Immunization Course

Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation

Utility of a Third Heplisav-B Dose in Patients with Inflammatory Bowel Disease without Immunity Following Two-Dose Heplisav-B Vaccination

Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B

Requirement for Further Validation on the Seroconversion of Hepatitis B Surface Antigen in Successful Vaccinees.

Immunomodulatory and Antiviral Therapy Improved Functional Cure Rate in CHB Patients with High HBsAg Level Experienced NA.

Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance

Hepatitis B vaccine immunogenicity in patients with chronic HCV infection at one year follow-up: the effect of interferon-alpha therapy

Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels

Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination

PreS antigen expression and anti-preS response in hepatitis B virus infections: relationship to serum HBV-DNA, intrahepatic HBcAg, liver damage and specific T-cell response

Serum Levels of Pres Antigen (hbpresag) in Chronic Hepatitis B Virus Infected Patients